<DOC>
	<DOCNO>NCT00652418</DOCNO>
	<brief_summary>The objective study compare efficacy Magnevist ( SH L 451 A ) dose 0.1 mmol/kg 0.2 mmol/kg contrast-enhanced 3D-Magnetic Resonance Angiography three region ( abdominal , femoral , leg region ) visualization artery , evaluate 179 assessable : cause contrast medium evaluation structural abnormality . Magnevist ( SH L 451 A ) administer intravenously crossover design patient arterial disease abdominal leg region . The safety 0.2 mmol/kg dose also assess .</brief_summary>
	<brief_title>Magnevist ( SH L 451A ) Intra-individual Dose Comparison Study Magnetic Resonance Angiography</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Patients schedule undergo contrastenhanced 3DMagnetic Resonance Angiography Patients ankle brachial pressure index ( ABPI ) 0.3 less Patients allergy contrast medium Patients serious hepatic impairment Patients serious renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Magnevist</keyword>
	<keyword>Magnetic Resonance Angiography</keyword>
	<keyword>Meglumine gadopentetate</keyword>
	<keyword>Determination effective dose MRA</keyword>
</DOC>